-- Earnings Flash (AVEO) AVEO ONCOLOGY Posts Q3 Revenue $15.2M, vs. Street Est of $13.8M
4:10PM ET 11/08/2021 MT Newswires...
Quotes Snapshot > AVEO
Aveo Pharmaceuticals Inc AVEO:NASDAQ
Last Price$6.50NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/26/21
Today's Change-0.03(0.46%)
Bid (Size)$6.00 (10)
Ask (Size)$6.50 (11)
Day Low / High$6.29 - 6.57
Volume103.0 K
Read more news Recent News
Aveo Pharmaceuticals' Head, Neck Cancer Drug Gets FDA Fast-Track Designation
9:23AM ET 9/20/2021 MT NewswiresAveo Pharmaceuticals (AVEO) said Monday the US Food and Drug Administration granted ficlatuzumab, its investigational drug being developed for the...
-- Earnings Flash (AVEO) AVEO ONCOLOGY Reports Q2 Revenue $7.6M, vs. Street Est of $6.96M
4:17PM ET 8/05/2021 MT Newswires...
--HC Wainwright Adjusts Price Target on AVEO Pharmaceuticals to $19 From $27, Keeps Buy Rating
7:23AM ET 7/12/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q3 2021 Results - Earning Call Transcript
7:56PM ET 11/08/2021 Seeking AlphaAVEO Pharmaceuticals: Sticking To The Plan
8:52AM ET 10/29/2021 Seeking AlphaAVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2021 Results - Earnings Call Transcript
9:20PM ET 8/05/2021 Seeking AlphaAVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
2:02AM ET 7/24/2021 Seeking AlphaCompany Profile
Business DescriptionAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 30 Winter Street Boston, Massachusetts 02108 |
| Phone | +1.617.400.0101 |
| Number of Employees | 17 |
| Recent SEC Filing | 11/08/2021 10-Q |
| President, Chief Executive Officer & Director | Michael P. Bailey |
| Chief Financial Officer | Erick J. Lucera |
| Vice President-Information Technology | Matthew Coulter |
| Head-Compliance | Stefanie Solomon |
Company Highlights
| Price Open | $6.33 |
| Previous Close | $6.53 |
| 52 Week Range | $4.95 - 18.24 |
| Market Capitalization | $223.4 M |
| Shares Outstanding | 34.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/15/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.98 |
| Beta vs. S&P 500 | N/A |
| Revenue | $5.4 M |
| Net Profit Margin | -225.54% |
| Return on Equity | -105.10% |
Analyst Ratings as of 11/06/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |